Polycystic Ovary Syndrome and the Metabolic Syndrome Long-Term Risks
January 2008
in “
Humana Press eBooks
”
Research cited in this study
5 / 5 results
research Finasteride Versus Cyproterone Acetate-Estrogen Regimens in the Treatment of Hirsutism
Finasteride and CPA-EE2 equally reduce hirsutism, but affect hormone levels differently.
research Polycystic Ovary Syndrome and Cardiovascular Disease: A Premature Association?
While PCOS might increase the risk of heart disease, there's not strong evidence to prove it causes earlier heart problems.
research Topical Eflornithine: Efficacy in Reducing Unwanted Facial Hair Growth in Women
Eflornithine cream effectively reduces women's unwanted facial hair but hair returns if treatment stops.
research Usefulness of a 12-Month Treatment with Finasteride in Idiopathic and Polycystic Ovary Syndrome-Associated Hirsutism
research Gonadotrophin-Releasing Hormone Agonist Therapy for Hirsutism Is as Effective as High Dose Cyproterone Acetate but Results in a Longer Remission
Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.